DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Nguyen G, Danser AH. Prorenin and (pro)renin receptor: A
review of available data from in vitro studies and experimental
models in rodents. Exp Physiol, 2008, 93:557–563.
Niimura F, Labosky PA, Kakuchi J, et al. Gene targeting in mice
reveals a requirement for angiotensin in the development and
maintenance of kidney morphology and growth factor regulation.
J Clin Invest, 1995, 96:2947–2954.
Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression
in humans by the orally active renin inhibitor
Aliskiren (SPP100): Comparison with enalapril. Hypertension,
2002, 39:E1–E8.
Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin
inhibitor, provides dose- dependent efficacy and sustained
24-hour blood pressure control in patients with hypertension.
J Am Coll Cardiol, 2007, 49:1157–1163.
ONTARGET Investigators. Telmisartan, ramipril, or both in
patients at high risk for vascular events. N Engl J Med, 2008,
358:1547–1559.
Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined
use of aliskiren and valsartan in patients with hypertension:
A randomised, double- blind trial. Lancet, 2007, 370:
221–229.
Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in
Type 2 Diabetes Using Cardio- Renal Endpoints (ALTITUDE):
Rationale and study design. Nephrol Dial Transplant, 2009,
24:1663–1671.
Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with
losartan in type 2 diabetes and nephropathy. N Engl J Med,
2008, 358:2433–2246.
Paul M, Poyan Mehr A, Kreutz R. Physiology of local reninangiotensin
systems. Physiol Rev, 2006, 86:747–803.
Perlman S, Costa- Neto CM, Miyakawa AA, et al. Dual agonistic
and antagonistic property of nonpeptide angiotensin AT 1
ligands: Susceptibility to receptor mutations. Mo. Pharmacol,
1997, 51:301–311.
Pfeffer MA, McMurray JJ, Velazquez EJ, et al., for the Valsartan
in Acute Myocardial Infarction Trial Investigators. Valsartan,
captopril, or both in myocardial infarction complicated by
heart failure, left ventricular dysfunction, or both. New Engl J
Med, 2003, 349:1893–1906.
Pilz BE, Shagdarsuren M, Wellner A, et al., Aliskiren, a human
renin inhibitor, ameliorates cardiac and renal damage in
double-transgenic rats. Hypertension, 2005, 46:569–576.
Pitt B, Poole- Wilson PA, Segal R, et al., on behalf of the ELITE
II investigators. Effect of losartan compared with captopril on
mortality in patients with symptomatic heart failure:
Randomized trial— the Losartan Heart Failure Survival Study
ELITE II. Lancet, 2000, 355:1582–1587.
Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan
versus captopril in patients over 65 with heart failure
(Evaluation of Losartan in the Elderly study, ELITE). Lancet,
1997, 349:747–752.
Ramser J, Abidi FE, Burckle CA, et al. A unique exonic splice
enhancer mutation in a family with X- linked mental retardation
and epilepsy points to a novel role of the renin receptor.
Hum Mol Genet, 2005, 14:1019–1027.
Rhaleb N- E, Peng H, Yang X- P, et al. Long- term effect of N-
acetyl-seryl-aspartyl-lysly-proline on left ventricular collagen
deposition in rats with two- kidney, one- clip hypertension.
Circulation, 2001, 103:3136–3141.
Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis
and treatment of diabetic nephropathy. Nat Rev
Nephrol, 2010, in press.
Ruiz- Ortega M, Esteban V, Egido J. The regulation of the inflammatory
response through nuclear factor- κB pathway by
angiotensin IV extends the role of the renin angiotensin system
in cardiovascular disease. Trends Cardiovasc Med, 2007,
17:19–25.
Sanoski CA. Aliskiren: An oral direct renin inhibitor for the treatment
of hypertension. Pharmacotherapy, 2009, 29:193–212.
Santos RA, Ferreira AJ, Simões ESAC. Recent advances in the
angiotensin- converting enzyme 2-angiotensin(1-7)-Mas axis.
Exp Physiol, 2008, 93:519–527.
Sayed- Tabatabaei FA, Oostra BA, Isaacs A, et al. ACE
Polymorphisms. Circ Res, 2006, 98:1123–1133.
Schmieder RE, Hilgers KF, Schlaich MP, et al. Reninangiotensin
system and cardiovascular risk. Lancet, 2007,
369:1208–1219.
Schneider AW, Kalk JF, Klein CP. Effect of losartan, an
angiotensin II receptor antagonist, on portal pressure in cirrhosis.
Hepatology, 1999, 29:334–339.
Sethi AA, Nordestgaard BG, Gronholdt M- LM, et al.
Angiotensinogen single nucleotide polymorphisms, elevated
blood pressure, and risk of cardiovascular disease.
Hypertension, 2003, 41:1202–1211.
Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the
direct renin inhibitor aliskiren, the angiotensin receptor
blocker losartan, or both on left ventricular mass in patients
with hypertension and left ventricular hypertrophy.
Circulation, 2009, 119:530–537.
Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet, 2006,
368:1449–1456.
Steen VD, Medsger TA Jr. Long- term outcomes of scleroderma
renal crisis. Ann Intern Med, 2000, 17:600–603.
Strasser RH, Puig JG, Farsang C, et al. A comparison of the tolerability
of the direct renin inhibitor aliskiren and lisinopril in
patients with severe hypertension. J Hum Hypertens, 2007,
21:780–787.
Testa MA, Anderson RB, Nackley JF, et al. Quality of life and
anti- hypertensive therapy in men: A comparison of captopril
with enalapril. New Engl J Med, 1993, 328:907–913.
Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin
II receptors and angiotensin II receptor antagonists.
Pharmacol Rev, 1993, 45:205–251.
Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of
angiotensin- converting enzyme: Cloning and functional
expression as a captopril- insensitive carboxypeptidase. J Biol
Chem, 2000, 275:33238–33243.
Vaidyanathan S, Jarugula V, Dieterich HA, et al. Clinical pharmacokinetics
and pharmacodynamics of aliskiren. Clin
Pharmacokinet, 2008, 47:515–531.
Vane JR. The history of inhibitors of angiotensin converting
enzyme. J Physiol Pharmacol, 1999, 50:489–498.
Varagic J, Trask AJ, Jessup JA, et al. New angiotensins. J Mol
Med, 2008, 86:663–671.
Viberti G, Wheeldon NM, for the MicroAlbuminuria
Reduction with VALsartan (MARVAL) study investigators.
Microalbuminuria reduction with valsartan in patients with
type 2 diabetes mellitus: A blood pressure–independent effect.
Circulation, 2002, 106:672–678.
743
CHAPTER 26
RENIN AND ANGIOTENSIN